Hunter Capital (HUNTER) Q3 2025 earnings summary

Executive summary

• Focused on investments in technology and life science companies, emphasizing strategic partnerships and long-term value creation.

• Registered two public subsidiaries for distribution and planned listing, enabling direct exposure to growth companies.

• Acquired options and shares in SynAct Pharma, strengthening position in life science investments.

Financial highlights

• Net revenue for Q3 2025 was 1.5 MSEK; for the nine-month period, 1.52 MSEK.

• EBITDA for Q3 was 524 TSEK; for the nine-month period, -1.05 MSEK.

• Result after financial items for Q3 was 4.26 MSEK; for the nine-month period, 35.46 MSEK.

• Earnings per share for Q3 was 0.94 SEK; for the nine-month period, 7.81 SEK.

• Cash and cash equivalents at period end were 2.17 MSEK; equity was 67.5 MSEK.

Outlook and guidance

• Plans to list one or both RTO subsidiaries within the year to provide a clear market platform and attract new investors.

• Continues to seek new opportunities for value creation in both the short and long term.